BRISDELLE از شرکت SEBELA IRELAND LTD

اطلاعات داروی نمایش داده شده مستقیما از دیتابیس اطلاعات دارویی سازمان غذا و دارو آمریکا (FDA) استخراج می شود و مرتبا به روز رسانی می شود
داروی نمایش داده شده مورد تایید FDA می باشد و اطلاعات ثبت آن در زیر قابل مشاهده است

New Drug Application (NDA): 204516

Company: SEBELA IRELAND LTD

Medication Guide

Summary Review

Products on NDA 204516

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code	RLD	RS
BRISDELLE	PAROXETINE MESYLATE	EQ 7.5MG BASE	CAPSULE;ORAL	Prescription	AB	Yes	Yes

Approval Date(s) and History, Letters, Labels, Reviews for NDA 204516

Original Approvals or Tentative Approvals

Action Date	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert	Notes	Url
06/28/2013	ORIG-1	Approval	Type 3 – New Dosage Form	STANDARD	Label (PDF) Letter (PDF) Review Summary Review (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204516s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204516Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204516Orig1s000TOC.cfm https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204516Orig1s000SumR.pdf

Action Date

Submission

Action Type

Submission Classification

Review Priority; Orphan Status

Letters, Reviews, Labels, Patient Package Insert

Notes

Url

06/28/2013

ORIG-1

Approval

Type 3 – New Dosage Form

STANDARD

Label (PDF)

Letter (PDF)

Review

Summary Review (PDF)

https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204516s000lbl.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/204516Orig1s000ltr.pdf
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204516Orig1s000TOC.cfm
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204516Orig1s000SumR.pdf

Supplements

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Note	Url
09/20/2021	SUPPL-11	Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204516s011lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/204516Orig1s011ltr.pdf
04/28/2017	SUPPL-5	Labeling-Package Insert, Labeling-Medication Guide	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s005lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/204516Orig1s005ltr.pdf
01/04/2017	SUPPL-4	Labeling-Medication Guide, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s004lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/204516Orig1s004ltr.pdf
12/01/2014	SUPPL-3	Labeling-Medication Guide, Labeling-Package Insert	Label (PDF) Letter (PDF)		https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204516s003lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/204516Orig1s003ltr.pdf
04/01/2014	SUPPL-2	Manufacturing (CMC)		Label is not available on this site.
12/19/2013	SUPPL-1	Manufacturing (CMC)		Label is not available on this site.

Labels for NDA 204516

Action Date	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Package Insert	Url
09/20/2021	SUPPL-11	Labeling-Package Insert	Label (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/204516s011lbl.pdf
04/28/2017	SUPPL-5	Labeling-Package Insert	Label (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s005lbl.pdf
04/28/2017	SUPPL-5	Labeling-Medication Guide	Label (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s005lbl.pdf
01/04/2017	SUPPL-4	Labeling-Medication Guide	Label (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s004lbl.pdf
01/04/2017	SUPPL-4	Labeling-Package Insert	Label (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/204516s004lbl.pdf
12/01/2014	SUPPL-3	Labeling-Medication Guide	Label (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204516s003lbl.pdf
12/01/2014	SUPPL-3	Labeling-Package Insert	Label (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204516s003lbl.pdf
06/28/2013	ORIG-1	Approval	Label (PDF)	https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204516s000lbl.pdf

Therapeutic Equivalents for NDA 204516

BRISDELLE

CAPSULE;ORAL; EQ 7.5MG BASE

TE Code = AB

Drug Name	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	RLD	TE Code	Application No.	Company
BRISDELLE	PAROXETINE MESYLATE	EQ 7.5MG BASE	CAPSULE;ORAL	Prescription	Yes	AB	204516	SEBELA IRELAND LTD
PAROXETINE MESYLATE	PAROXETINE MESYLATE	EQ 7.5MG BASE	CAPSULE;ORAL	Prescription	No	AB	207139	ACTAVIS LABS FL INC
PAROXETINE MESYLATE	PAROXETINE MESYLATE	EQ 7.5MG BASE	CAPSULE;ORAL	Prescription	No	AB	207188	PRINSTON INC

حتما بخوانید : CEFOTETAN از شرکت WEST-WARD PHARM CORP

منبع : www.accessdata.fda.gov

بخوانید BUPROPION HYDROCHLORIDE از شرکت JUBILANT GENERICS

BRISDELLE از شرکت SEBELA IRELAND LTD